Scholarlink

Objective <p>We report a case of cefazolin-induced coagulopathy, highlighting the importance of maintaining a high index of suspicion for this rare adverse effect of cefazolin.</p> Setting <p>Department of intensive care, Rabin Medical Center, Hasharon Hospital, Petach Tikvah, Israel.</p> Patient <p>A patient presented with shortness of breath, pleural effusion, iatrogenic pneumothorax, and bacteremia (positive for coagulase-negative staphylococcus).</p> Interventions <p>Multiple thoracic drains and high-dose cefazolin therapy (2 gr intravenously three times per day).</p> Case report <p>A 78-year-old Caucasian woman with a history of mild renal dysfunction, chronic obstructive pulmonary disease, and morbid obesity was admitted to the Emergency Medicine Ward with new-onset shortness of breath. Initial evaluation revealed pleural effusion and positive blood cultures for Staphylococcus lugdunensis. Consequently, high-dose intravenous cefazolin (2 gr three times per day) was initiated. The patient’s clinical condition deteriorated, necessitating mechanical ventilation and continuous renal replacement therapy in the intensive care unit. Management included echocardiography, placement of three pleural drains to address pneumothoraces, and intravenous antibiotic therapy. On the fourth day of cefazolin treatment, the patient experienced a significant rise in international normalized ratio (inr = 20 at day 4) levels, reaching 15–20, despite the absence of overt bleeding. After ruling-out primary hematologic disorders, cefazolin-induced coagulopathy was suspected. Cefazolin was discontinued, and vitamin K supplementation was promptly administered. This intervention led to a rapid normalization of international normalized ratio levels.</p> Conclusion <p>Cefazolin-induced coagulopathy is a potentially life-threatening complication that may present with or without overt bleeding a few days after initiating intravenous cefazolin therapy. Owing to its rarity, this adverse effect requires heightened awareness and familiarity with predisposing risk factors to ensure timely recognition and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cefazolin-induced coagulopathy: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Olivier Zerbib,
  • Daniel Kovarsky,
  • Michael Oshrov,
  • Smadja Pierre,
  • lev Shaoul

摘要

Objective

We report a case of cefazolin-induced coagulopathy, highlighting the importance of maintaining a high index of suspicion for this rare adverse effect of cefazolin.

Setting

Department of intensive care, Rabin Medical Center, Hasharon Hospital, Petach Tikvah, Israel.

Patient

A patient presented with shortness of breath, pleural effusion, iatrogenic pneumothorax, and bacteremia (positive for coagulase-negative staphylococcus).

Interventions

Multiple thoracic drains and high-dose cefazolin therapy (2 gr intravenously three times per day).

Case report

A 78-year-old Caucasian woman with a history of mild renal dysfunction, chronic obstructive pulmonary disease, and morbid obesity was admitted to the Emergency Medicine Ward with new-onset shortness of breath. Initial evaluation revealed pleural effusion and positive blood cultures for Staphylococcus lugdunensis. Consequently, high-dose intravenous cefazolin (2 gr three times per day) was initiated. The patient’s clinical condition deteriorated, necessitating mechanical ventilation and continuous renal replacement therapy in the intensive care unit. Management included echocardiography, placement of three pleural drains to address pneumothoraces, and intravenous antibiotic therapy. On the fourth day of cefazolin treatment, the patient experienced a significant rise in international normalized ratio (inr = 20 at day 4) levels, reaching 15–20, despite the absence of overt bleeding. After ruling-out primary hematologic disorders, cefazolin-induced coagulopathy was suspected. Cefazolin was discontinued, and vitamin K supplementation was promptly administered. This intervention led to a rapid normalization of international normalized ratio levels.

Conclusion

Cefazolin-induced coagulopathy is a potentially life-threatening complication that may present with or without overt bleeding a few days after initiating intravenous cefazolin therapy. Owing to its rarity, this adverse effect requires heightened awareness and familiarity with predisposing risk factors to ensure timely recognition and management.